Warfvinges väg 35
About BioArctic ABBioArctic AB is a Swedish privately held research-based biopharmaceutical company founded in 2003. The company’s mission is to provide new and effective treatments for patients with disorders in the central nervous system. Its proprietary technology and dedicated personnel have made it possible to develop new immunotherapeutic approaches to neurodegenerative diseases. We focus on therapy areas with a large medical need such as Alzheimer’s disease, Parkinson’s disease and spinal cord injury.
CEO: Gunilla Osswald
CSO: Christer Möller
CMO: Hans Basun
Please click here for BioArctic job opportunities.
Please click here for clinical trial information.
43 articles with BioArctic AB
BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease
BioArctic AB announced today that the company has received a Notice of Option Exercise under the Research, Development, Option and License Agreement dated as of September 15, 2016 between AbbVie (NYSE: ABBV) and BioArctic.
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018
BioArctic AB to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at 08:00 a.m. CET.
BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference
BAN2401 is a selective anti-amyloid beta (Aβ) protofibril antibody.
BioArctic is Granted a Concept Patent in Europe for the Company's Strategy for Disease-modifying Treatment of Parkinson's Disease
BioArctic AB announced today that the European Patent Office (EPO) has issued a decision to grant the company's patent application in Europe, EP09738534.8, for its Parkinson's disease concept patent. The decision states that the European patent, EP 2 282 758 B1, will enter into force on November 21, 2018.
BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD
BioArctic AB announced today that Eisai will present additional data on the anti-amyloid (Aβ) protofibril antibody BAN2401 clinical Phase 2b study at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference, October 24-27, 2018 in Barcelona, Spain.
BioArctic Signs a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease
Collaboration is to develop new and improved diagnostic methods for Alzheimer's disease by identifying and measuring new biomarkers in cerebrospinal fluid (CSF) and blood.
BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides an opportunity to develop novel treatments for Alzheimer's disease.
BioArctic Announces Detailed Results of the BAN2401 Phase 2b Study in Early Alzheimer's Disease Presented at AAIC 2018
BioArctic AB announced on July 6 the positive topline results from the clinical Phase 2b study with BAN2401 in 856 patients with early Alzheimer's disease.
BioArctic: Late Breaking Phase 2b Study Results of BAN2401 in Alzheimer's Disease Will be Webcast Live From AAIC 2018 by Eisai
BioArctic AB, the BAN2401 Phase 2b clinical study results will be presented in an oral session at the 2018 Alzheimer's Association International Conference (AAIC) on July 25, 2018 at 3:30 p.m. CDT in Chicago, IL
BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury
BioArctic AB announced that the company has received approval by Fimea and Valvira for inclusion of Finnish patients in BioArctic's ongoing clinical Phase 1/2 study with SC0806.
BioArctic AB announces the results of the BAN2401 Phase 2b clinical study (ClinicalTrials.gov identifier NCT01767311), will be presented in an oral session at the 2018 Alzheimer's Association International Conference (AAIC) on July 25, 2018 at 3:30 p.m. CDT in Chicago, IL
BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease
The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer's disease demonstrated statistically significant and dose-dependent slowing in clinical decline and reduction of amyloid beta accumulated in the brain
BioArctic Extends the Research Collaboration With Uppsala University Regarding New Antibody Technology
BioArctic AB today announced that the company has signed an extended research collaboration agreement with Uppsala University, Department of Pharmaceutical Biosciences.
Continued progress of the project portfolio
Inclusion completed of patients with complete spinal cord injury in the first panel of BioArctic's ongoing study
BioArctic AB announced today that the inclusion of patients with complete spinal cord injury in the first panel has been completed in the company's ongoing clinical Phase 1/2 study.
BioArctic Receives Regulatory Approval in Norway for a Clinical Study in Patients With Complete Spinal Cord Injury
The candidate product is a combination of a medical device (implant) and a medicinal product (FGF1) for patients with complete spinal cord injury.
BioArctic Receives U.S. Patent Protection for a Method With a Medical Device for Treatment of Patients With Complete Spinal Cord Injury
The notification states that the US patent 9,895,234 will be granted and enters into force on February 20, 2018.
BioArctic, a Company in Karolinska Development's Portfolio, Announces That the Phase IIb Study of BAN2401 in Early Alzheimer's Disease Continues Toward 18-Month Endpoint
Karolinska Development announces today that BioArctic's drug candidate BAN2401 did not meet the criteria for success at a 12-month interim analysis of a Phase IIb study in patients with early Alzheimer's Disease.
Net sales for the period amounted to SEK 31.5M.
BioArctic's Patent For Its Product Candidate Antibody BAN0805, For Parkinson's Disease, Is Now Granted In Europe